BR112022000347A2 - Vacinas de ehrlichia e composições imunogênicas - Google Patents

Vacinas de ehrlichia e composições imunogênicas

Info

Publication number
BR112022000347A2
BR112022000347A2 BR112022000347A BR112022000347A BR112022000347A2 BR 112022000347 A2 BR112022000347 A2 BR 112022000347A2 BR 112022000347 A BR112022000347 A BR 112022000347A BR 112022000347 A BR112022000347 A BR 112022000347A BR 112022000347 A2 BR112022000347 A2 BR 112022000347A2
Authority
BR
Brazil
Prior art keywords
ehrlichia
immunogenic compositions
vaccines
canis
adjuvant
Prior art date
Application number
BR112022000347A
Other languages
English (en)
Inventor
M Mwangi Duncan
J Millership Jason
W Mcbride Jere
Joseph Dominowski Paul
Sharath Rai
M Wappel Sharon
Suman Mahan
Original Assignee
Res Found Dev
Zoetis Services Llc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Res Found Dev, Zoetis Services Llc filed Critical Res Found Dev
Publication of BR112022000347A2 publication Critical patent/BR112022000347A2/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/12—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from bacteria
    • C07K16/1203—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from bacteria from Gram-negative bacteria
    • C07K16/1246—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from bacteria from Gram-negative bacteria from Rickettsiales (O)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A61K39/0233—Rickettsiales, e.g. Anaplasma
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/39—Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
    • C07K14/29—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Richettsiales (O)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04—Linear peptides containing only normal peptide links
    • C07K7/06—Linear peptides containing only normal peptide links having 5 to 11 amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/52—Bacterial cells; Fungal cells; Protozoal cells
    • A61K2039/521—Bacterial cells; Fungal cells; Protozoal cells inactivated (killed)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/55—Medicinal preparations containing antigens or antibodies characterised by the host/recipient, e.g. newborn with maternal antibodies
    • A61K2039/552—Veterinary vaccine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55561—CpG containing adjuvants; Oligonucleotide containing adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55577—Saponins; Quil A; QS21; ISCOMS
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/70—Multivalent vaccine
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Microbiology (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Mycology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Peptides Or Proteins (AREA)

Abstract

vacinas de ehrlichia e composições imunogênicas. a presente invenção refere-se a composições imunogênicas que podem ser usadas, em alguns aspectos, para induzir uma resposta imunológica contra um ehrlichia como o ehrlichia canis. em algumas concretizações, a composição imunogênica compreende uma bacterina e. canis e/ou adjuvante, como por exemplo, uma emulsão ou um adjuvante lipossomal. métodos relacionados, como para diagnóstico ou vacinação contra ehrlichiosis, também são fornecidos.
BR112022000347A 2019-07-12 2020-07-13 Vacinas de ehrlichia e composições imunogênicas BR112022000347A2 (pt)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US201962873843P 2019-07-12 2019-07-12
US201962879762P 2019-07-29 2019-07-29
US202063049476P 2020-07-08 2020-07-08
PCT/US2020/041779 WO2021011456A1 (en) 2019-07-12 2020-07-13 Ehrlichia vaccines and immunogenic compositions

Publications (1)

Publication Number Publication Date
BR112022000347A2 true BR112022000347A2 (pt) 2022-04-12

Family

ID=71948757

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112022000347A BR112022000347A2 (pt) 2019-07-12 2020-07-13 Vacinas de ehrlichia e composições imunogênicas

Country Status (10)

Country Link
US (1) US20220356231A1 (pt)
EP (1) EP3996741A1 (pt)
JP (1) JP2022540197A (pt)
CN (1) CN114514238A (pt)
AU (1) AU2020314625A1 (pt)
BR (1) BR112022000347A2 (pt)
CA (1) CA3146842A1 (pt)
CL (1) CL2022000086A1 (pt)
MX (1) MX2022000525A (pt)
WO (1) WO2021011456A1 (pt)

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6043085A (en) * 1998-08-27 2000-03-28 Research Development Foundation Ehrlichia canis 120-kDa immunodominant antigenic protein and gene
ES2293057T3 (es) * 2002-11-04 2008-03-16 Research Development Foundation Antigenos p153 y p156 para la inmunodiagnosis de ehrliquiosis canina y humana y uso de los mismos.
US20050202046A1 (en) * 2004-03-11 2005-09-15 Wyeth Canine vaccine for protection against ehrlichiosis
US7842474B2 (en) * 2005-04-04 2010-11-30 Idexx Laboratories, Inc. Ehrlichia canis DIVA (differentiate infected from vaccinated animals)
EP3527582B1 (en) * 2005-04-04 2022-08-17 IDEXX Laboratories, Inc. Ehrlichia canis diva (differentiate infected from vaccinated animals)
US8591906B2 (en) * 2005-06-16 2013-11-26 Research Development Foundation Immunoreactive protein orthologs of Ehrlichia canis and E. chaffeensis
WO2008000070A1 (en) * 2006-06-27 2008-01-03 Wellington Laboratories Inc. Glycyrrhetinic acid derivatives
EP2064231B2 (en) * 2006-08-31 2020-08-26 Research Development Foundation Immunoreactive glycoprotein gp19 of ehrlichia canis
MX349720B (es) * 2008-06-27 2017-08-09 Zoetis Services Llc Composiciones adyuvantes novedosas.
US8329189B2 (en) * 2009-04-28 2012-12-11 Research Development Foundation Immunoreactive Ehrlichia p120/p140 epitopes and uses thereof
BR112012030337B1 (pt) * 2010-05-28 2021-04-27 Coley Pharmaceutical Group, Inc Vacina compreendendo um ou mais oligonucleotídeo(s) de cpg isolado(s) ou um agonista de tlr e colesterol, e uso da mesma
EP2433646A1 (en) * 2010-09-22 2012-03-28 Intervet International BV Vaccine against Ehrlichia canis and associated methods
US10632189B2 (en) * 2012-05-31 2020-04-28 Zoetis Services Llc Canine respiratory coronavirus for treatment and protection against bacterial infections
WO2015042423A2 (en) * 2013-09-19 2015-03-26 Zoetis Llc Vaccine
AU2019311181A1 (en) * 2018-07-27 2021-02-18 Research Development Foundation Chimeric immunogenic polypeptides

Also Published As

Publication number Publication date
US20220356231A1 (en) 2022-11-10
JP2022540197A (ja) 2022-09-14
EP3996741A1 (en) 2022-05-18
WO2021011456A1 (en) 2021-01-21
AU2020314625A1 (en) 2022-02-03
CN114514238A (zh) 2022-05-17
MX2022000525A (es) 2022-04-20
CL2022000086A1 (es) 2022-09-30
CA3146842A1 (en) 2021-01-21

Similar Documents

Publication Publication Date Title
BR112018013387A2 (pt) vetor de vacinação recombinante, vírus mva, vacina ou composição farmacêutica e kit
BRPI1013780B8 (pt) Composição imunogênica útil para imunização contra staphylococcus aureus, seu método de preparação e composição farmacêutica
CL2019003264A1 (es) Formulaciones para vacunas contra la neoplasia y métodos para preparar las mismas. (divisional solicitud 201703151)
BR112018004242A2 (pt) composições de vacina que possuem estabilidade e imunogenicidade aumentadas
CL2019003805A1 (es) Composiciones inmunógenas de senecavirus a y métodos de éstas.
TW201612316A (en) Porcine pseudorabies virus gene deletion strain, vaccine composition, and preparation method and application of vaccine composition
AU2015296298A8 (en) Flagellin-based agents and uses including effective vaccination
BR112019014397A2 (pt) Composições de neisseria meningitidis e métodos das mesmas
BR112014024533A2 (pt) vacina contra mycoplasma hyopneumoniae
BR112013022397A2 (pt) vacinas combinadas com doses menores de antígeno e/ou adjuvante
AR089797A1 (es) Vacunas contra clostridum difficile que comprenden toxinas recombinantes
BR112015005056A2 (pt) vacinas de combinação com sorogrupo b meningococcus e d/t/p
BR112018075440A2 (pt) composições e métodos para prevenir e tratar a infecção por zika vírus
BR112016015422A2 (pt) formulações de vacina de frasco único
BR112015009070A2 (pt) proteína de fusão ou coquetel de antígenos; uso de uma proteína de fusão ou um coquetel de antígenos; vacina; e método para imunizar um animal, que inclui um ser humano, contra tuberculose causada por microbactérias virulentas
CL2011002639A1 (es) Cepa bacteriana de mycoplasma bovis atenuada avirulenta; composicion inmunogenica que la comprende; y uso para fabricar un medicamento para infecciones producidas por m. bovis.
CO6361948A2 (es) Uso de antigeno de mycoplasma bovis
BR112019003992A2 (pt) vacina contra neisseria meningitidis
BR112015021523A8 (pt) composição de uma vacina contra a tosse convulsa acelular, e, usos da composição e de antígenos da bordetella pertussis
MX2016016746A (es) Composiciones de vacuna con adyuvante dual, preparacion y usos.
AR099960A1 (es) Procedimientos y composición farmaceutica para inducir una respuesta inmunitaria
MX2016001695A (es) Composiciones inmunogenas de combinacion.
BR112018069100A2 (pt) uma vacina combinada contra a infecção por vírus pcv2 e mycoplasma hyopneumoniae
BR112018074910A2 (pt) composição imunológica, e, método de indução de uma resposta imunológica contra o vírus da influenza equina em um sujeito
PL404247A1 (pl) Koniugat oligocukru LOS Bordetella pertussis i toksyny krztuśca i jego zastosowanie w profilaktyce i leczeniu zakażeń wywoływanych przez Bordetella pertussis